Clinical trials
catalyst calendar across sponsors →Studies where OM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 3 observational · 1 with posted results
Held by 9 tracked-famous managers (AQR CAPITAL MANAGEMENT LLC, MARSHALL WACE, LLP, MILLENNIUM MANAGEMENT LLC, JANE STREET GROUP, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, +4 more) · FINRA short interest 11.0 days to cover (settled 2026-07-31) · insider 90d: 0 buys / 1 sells · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Home With TablO outcoMEs (HOME) RegistryNCT04526301observationalWeekly Standardized Dialysis Adequacy | — | Unknown status | Device: Tablo Hemodialysis System | End Stage Renal Disease | 500 | 2024-07-31 | 2022-09-23 |
| Comparative Outcome Measures of Patients Receiving Acute Renal ThErapy StudyNCT04912024observationalBUN Lab Value | — | Completed | Device: Intermittent Renal Replacement Therapy using the Tablo Hemodialysis System, Intermittent Renal Replacement Therapy using Conventional Hemodialysis Systems | End Stage Kidney Disease, End Stage Renal Disease, Acute Kidney Injury | 458 | 2022-06-15actual | 2022-08-12 |
| EXtension of Tablo TrEatmeNt Duration RegistryNCT04912050observationalTreatment Success | — | Completed | Device: Tablo Hemodialysis System | End Stage Renal Disease (ESRD), End Stage Renal Disease on Dialysis, Acute Kidney Injury | 33 | 2022-05-31actual | 2022-08-12 |
| The Study of Intradialytic Symptoms in Subjects Treated With Qd 500vs Qd 300NCT05947708Adequacy of Chronic DialysisRandomized · Single-masked · TreatmentStudy Protocol ↗ | Not applicable | Completed | Device: Dialysate Flow Rate | End Stage Renal Disease on Dialysis | 41 | 2019-10-15actual | 2023-07-17 |
| The EvAluation of TaBlo In-CLinic and In-HOmeNCT02460263results2020-07-01Weekly Standardized Dialysis AdequacyNon-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Tablo Hemodialysis System | End Stage Renal Disease | 30 | May 2019actual | 2020-07-01 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19